Navigation Links
BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
Date:5/7/2012

LYNBROOK, N.Y., May 7, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, announced today a rescheduled date and time for its conference call and live audio webcast to report its first quarter 2012 financial results and provide a corporate update. The conference call is now scheduled for 4:30 p.m. EDT on Thursday, May 10, 2012. The Company will issue a financial results press release earlier that afternoon.

In order to participate in the conference call, please dial 1-800-860-2442 (domestic) or 1-412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com, or you may use the link: http://www.videonewswire.com/event.asp?id=86553.

A replay of the call will be available one hour after the end of the conference on May 10, 2012 until 9:00 a.m. EDT on May 23, 2012. To access the replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and reference the access code 10013068. The archived webcast will be available for 90 days in the Investor Relations section of BioSpecifics' website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Today, injectable collagenase, registered as XIAFLEX®, is marketed in the U.S. for the treatment of Dupuytren's contracture in adults with a palpable cord by the Company's partner Auxilium Pharmaceuticals, Inc. (Auxilium) and is marketed in Europe under the trademark XIAPEX® by Pfizer Ltd. (Pfizer). XIAFLEX will be tested in the clinic for six promising indications during 2012: Auxilium is developing XIAFLEX for the treatment of Peyronie's disease, which is currently in Phase III pivotal clinical trials, as well as for frozen shoulder (adhesive capsulitis) and cellulite, which are in Phase II and Phase I, respectively. Auxilium is also conducting a Phase IIIb trial of XIAFLEX for Dupuytren's contracture patients with multiple palpable cords. BioSpecifics is developing XIAFLEX for human and canine lipomas. Pfizer has development and commercialization rights for XIAPEX for Dupuytren's contracture and Peyronie's disease in the 27 European Union member countries and 19 other European and Eurasian countries. Asahi Kasei Pharma Corporation has development and commercialization rights for XIAFLEX for the same two indications in Japan, and Actelion Pharmaceuticals has development and commercialization rights for XIAFLEX for these two indications in Canada, Australia, Brazil and Mexico. More information about the Company may be found on its website at www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico
2. BioSpecifics Technologies Corp. to Present at Lazard Capital Markets 8th Annual Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
4. BioSpecifics Technologies Corp. Reports Second Quarter 2011 Financial Results
5. BioSpecifics Technologies Corp. Announces Board Authorization of up to $2 Million Share Repurchase Program
6. BioSpecifics Technologies Corp. to Present at Jefferies 2011 Global Healthcare Conference
7. BioSpecifics Announces Positive XIAPEX® Data Presented at XVI Annual Federation of European Societies for Surgery of the Hand Congress
8. BioSpecifics Technologies Corp. Provides Update on XIAPEX® Launch Progress in EU
9. BioSpecifics Technologies Corp. to Present at SEVEN, Noble Financial Capital Markets Seventh Annual Equity Conference
10. BioSpecifics Technologies Corp. Announces Launch of XIAPEX® by Pfizer for Treatment of Dupuytrens Contracture in Europe
11. BioSpecifics Technologies Corp. to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc ... reached agreements to resolve virtually all known U.S. mesh ... discussions to resolve the known remaining U.S. claims at ... payments beginning in the fourth quarter of 2017 and ... of its second quarter 2017 results, the Company intends ...
(Date:8/4/2017)... Aug. 3, 2017  Agragen, LLC, a ... in the biopharmaceutical, nutraceutical, and aquacultural feed sectors, ... its lead drug candidates, AGR131.  This drug is ... from the blood of patients suffering from inflammatory ... bowel disease. ...
(Date:8/2/2017)... Aug. 2, 2017 Fenita J. ... as a Pinnacle Lifetime Professional in the Field ... Manager at Turing Pharmaceuticals, AG. Her skills and ... relationship building.                ... 25 years of experience as a highly successful ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... “Emotions are sacred, valid, honored, encouraged. This ... positive education company Generation Mindful. To help change the mindset of parents and educators ... skills, she created the Time-In Toolkit, which launched on Kickstarter 3 weeks ago and ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... Alcovit, a ... to ramp up its marketing efforts with its product now available through Jet.com. ... to the public. The effervescent powdered drink is designed to quickly detox the body ...
(Date:8/18/2017)... ... ... “Our Mountains to Climb: A Journey of Love and Faith Through Trials”: ... faith they shared to overcome struggles in life. “Our Mountains to Climb: A Journey ... Corcoran, a retired teacher and happily married since 1999; the author’s personal experiences drive ...
(Date:8/18/2017)... ... ... “Beyond Our Imaginations: The Infinite God”: shows the importance of God in living ... of published author, Mark Lawrence, born in Michigan, the author has lived in various ... greater man of God is that I have to be more mindful of feminine ...
(Date:8/18/2017)... ... ... Mandate for Kingdom Builders”: a call to walk as citizens of the Kingdom and ... published author, John F. McGeorge, Jr. Dr. John F. McGeorge Jr., B.A., J.D., ... three decades training pastors and Christian leaders. He also met his wife, Valerija, ...
Breaking Medicine News(10 mins):